PubMed Health⌕ Search

Biomedical subjects

N Macleod

Publications and source records attributed to N Macleod.

8 recordsLinked to original sources

The role of stasis in the clotting of blood and milk flows around solid objects.

A milk preparation has been used previously as an analogue for the study of flow related thrombosis in vitro. This paper describes further experiments to determine the comparability of milk clotting and thrombosis and to investigate the hydrodynamic correlates of milk clot deposition. An objective was to establish a standard in vitro test for thrombogenicity, thus facilitating the search for athrombogenic designs for prosthetic valves and other devices. Milk clotting in steady and pulsatile flow around four simple bodies of revolution showed many similarities of location and extent with in vivo canine thrombosis formation around similar bodies. A dye injection investigation of the fluid residence time distribution under the hydrodynamic conditions of the milk flow experiments showed that a permanent or trapped vortex persisted at each downstream site where clot was found, implying that stasis, or stagnation, is of predominant importance in causing milk clotting. Supplementary experiments with milk, using a modified Lee-White test, likewise showed that mixing promoted coagulation only after a certain fixed induction period from activation of the clotting process. Thus clot deposition is promoted by mixing which follows a constant induction period, rather than by mixing during an induction phase. This is a significant modification of the previous hypothesis.

Animals↗

A blood analogue for the experimental study of flow-related thrombosis at prosthetic heart valves.

It is shown that a flowing mixture of unpasteurised cow's milk, rennet and calcium chloride will deposit solid clot in vitro in the neighbourhood of certain kinds of flow obstruction and hydrodynamic disturbance particularly associated with deposition and thrombus formation in a similar stream of blood. The milk and blood deposits are similar in physical structure, both on a microscopic and a gross scales. For established kinds of artificial heart valves, the growth sequence and developed patterns of milk clotting obtained in vitro with pulsatile flows at physiological rates closely resemble patterns of thrombus reported clinically for valves of the same type in vivo. It appears that these phenomena, for which a tentative explanation is outlined, can form the basis of a convenient and rapid experimental method for evaluating in vitro the effects of design changes on the thrombogenicity of artificial heart valves and other cardiovascular devices in vivo. The milk system also shows promise as an aid in fundamental experimental studies of mechanisms of flow-related thrombosis.

Animals↗

Triazolam: monitored release in the United Kingdom.

1 A monitored release for triazolam was carried out in the United Kingdom during 1979. Three thousand and ten patients were involved--approximately one-third were males and two-thirds were females. 2 The majority of patients (71.3%) took 0.25 mg triazolam: 24.1% took 0.125 mg and only 4.4% took 0.5 mg and above. There were no differences between the sexes, but there were differences according to age. In the group over 60 y, 45.4% took 0.25 mg and 50.7% took 0.125 mg. 3 The majority of patients (84.7%) reported an adequate night's sleep, and the overall incidence of side effects in patients taking the drug was 12.2%.

Adolescent↗

The principles and in vivo performance of the Edinburgh pivoted aerofoil-disc prosthetic heart valve.

Prototypes of the Edinburgh prosthetic heart valve, known from previous experiments in vitro to promote exceptionally smooth and undisturbed forward flow, have been shown here in canine experiments to possess hemodynamic characteristics not inferior to those of the Bjork-Shiley valve (a present standard of excellence). In addition, we report a low incidence of valve thrombus deposition among calves in which this prototype valve, fabricated from the conventional materials, Delrin and stainless steel, has been implanted in the tricuspid site for up to 100 days without use of anticoagulants. This suggests that the design of the valve is such as to render it of low thrombogenicity. The new valve is designed for fabrication throughout in vitreous or pyro-coated carbon, materials of very high inherent athrombogenicity. It appears from the results discussed here that the developed form of the prosthesis, composed wholly of these athrombogenic materials, is likely to have both acceptable hemodynamic characteristics and an exceptionally low tendency to form thrombus. The introduction of such valves promises to be very advantageous and the results given here appear to warrant their development as the next stage of this program.

Animals↗